GRDX
GridAI Technologies Corp.
Healthcare — Biotechnology
GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based in Edinburgh, United Kingdom.
None
$3.44
$-0.24 (-6.57%)
Price History
52-Week Range
Sign in to add GRDX to a watchlist or set price alerts.
Fundamentals
| Market Cap | $29.65M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-4.14 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 31.6 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $6.93 |
| 52-Week Low | $1.08 |
| 50-Day Avg | $4.21 |
| 200-Day Avg | $3.53 |
| Avg Volume | 107.1K |
| Volume | 23.0K |
Performance Analysis
NEUTRALGRDX presents a mixed picture with both positive and negative indicators.
~
Trading at 40% of its 52-week range.
~
RSI at 31.6 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:12 UTC
Back to Screener Export Report